Division of Cell Genetics, Department of Pharmacology and Genetics, Medical University Innsbruck, Innsbruck, Tyrol, Austria.
Front Immunol. 2012 Aug 6;3:220. doi: 10.3389/fimmu.2012.00220. eCollection 2012.
It is well established that members of the protein kinase C (PKC) family seem to have important roles in T cells. Focusing on the physiological and non-redundant PKC functions established in primary mouse T cells via germline gene-targeting approaches, our current knowledge defines two particularly critical PKC gene products, PKCθ and PKCα, as the "flavor of PKC" in T cells that appear to have a positive role in signaling pathways that are necessary for full antigen receptor-mediated T cell activation ex vivo and T cell-mediated immunity in vivo. Consistently, in spite of the current dogma that PKCθ inhibition might be sufficient to achieve complete immunosuppressive effects, more recent results have indicated that the pharmacological inhibition of PKCθ, and additionally, at least PKCα, appears to be needed to provide a successful approach for the prevention of allograft rejection and treatment of autoimmune diseases.
已经证实,蛋白激酶 C(PKC)家族的成员似乎在 T 细胞中发挥着重要作用。通过对原发性小鼠 T 细胞进行种系基因靶向处理,关注具有生理功能且无冗余的 PKC 功能,目前的知识将两种特别关键的 PKC 基因产物,即 PKCθ 和 PKCα,定义为 T 细胞中 PKC 的“风味”,它们似乎在信号通路中发挥积极作用,这些信号通路对于完全抗原受体介导的 T 细胞体外激活和体内 T 细胞介导的免疫是必需的。一致的是,尽管目前存在 PKCθ 抑制可能足以实现完全免疫抑制作用的观点,但最近的结果表明,PKCθ 的药理学抑制,以及至少 PKCα 的抑制,似乎是预防同种异体移植物排斥和治疗自身免疫性疾病的成功方法所必需的。